LAS VEGAS and BUENOS AIRES, Argentina, Jan. 13, 2011 /PRNewswire/ -- Cord Blood America, Inc. (http://www.cordblood-america.com) (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that Biocordcell Argentina S.A. (BioCells, Inc.) has launched a program to store dental pulp stem cells, the first stem cell storage bank in Argentina to offer this service.
Cord Blood America announced in September 2010 that it purchased 50.1 percent, controlling interest, of BioCells, Inc., which is Argentina's second largest stem cell storage company, is profitable, and has affiliates under development throughout South America.
Dental pulp is the soft living tissue inside a tooth and stem cells are found in this tissue. Because this particular type of stem cell can differentiate into a variety of other cell types, research is ongoing on using these cells to generate nerve tissue, to repair muscle, and to generate bone and cartilage.
Researchers at the Yerkes National Primate Research Center, Emory University, have discovered dental pulp stem cells can stimulate growth and generation of several types of neural cells. Findings from this study, suggest dental pulp stem cells show promise for use in cell therapy and regenerative medicine, particularly therapies associated with the central nervous system.
"BioCells is pleased to launch this service to the many families of Argentina looking to store new and additional sources of stem cells for future use," said Diego Rissola, President of BioCells, Inc. "Capturing dental pulp cells for potential future regenerative purposes we believe will be seen as a great value added service complementing our successful cord blood business."
"We are pleased by this diversification of our revenue stream and believe it is an excellent way to begin 2011," said Matthew Schissler, Chairman, CEO and co-founder of Cord Blood America.
About Cord Blood America
Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.
Paul Knopick E & E Communications 949/707-5365 email@example.com
SOURCE Cord Blood America, Inc.